WallStSmart

Immunocore Holdings Ltd (IMCR)vsInsmed Inc (INSM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 52% more annual revenue ($606.42M vs $400.02M). INSM leads profitability with a -2.1% profit margin vs -8.9%. IMCR earns a higher WallStSmart Score of 43/100 (D).

IMCR

Hold

43

out of 100

Grade: D

Growth: 8.0Profit: 2.5Value: 5.0Quality: 5.0

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

IMCR1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
24.3%8/10

Revenue surging 24.3% year-over-year

INSM0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

IMCR4 concerns · Avg: 2.5/10
Market CapQuality
$1.52B3/10

Smaller company, higher risk/reward

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Return on EquityProfitability
-9.6%2/10

ROE of -9.6% — below average capital efficiency

Free Cash FlowQuality
$-35.53M2/10

Negative free cash flow — burning cash

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : IMCR

The strongest argument for IMCR centers on Revenue Growth. Revenue growth of 24.3% demonstrates continued momentum.

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bear Case : IMCR

The primary concerns for IMCR are Market Cap, Operating Margin, Return on Equity.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Key Dynamics to Monitor

IMCR profiles as a growth stock while INSM is a turnaround play — different risk/reward profiles.

INSM carries more volatility with a beta of 1.17 — expect wider price swings.

IMCR is growing revenue faster at 24.3% — sustainability is the question.

IMCR generates stronger free cash flow (-36M), providing more financial flexibility.

Bottom Line

IMCR scores higher overall (43/100 vs 39/100) and 24.3% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Immunocore Holdings Ltd

HEALTHCARE · BIOTECHNOLOGY · USA

Immunocore Holdings Limited, an advanced stage biotechnology company, develops immunotherapies for the treatment of cancer, infectious and autoimmune diseases. The company is headquartered in Abingdon, the United Kingdom.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Want to dig deeper into these stocks?